소외열대질환 치료 시장 규모, 점유율, 동향 분석 보고서 : 질환별, 제품별, 지역별, 부문별 예측(2025-2033년)

Neglected Tropical Disease Treatment Market Summary

The global neglected tropical disease treatment market size was estimated at USD 3.96 billion in 2024 and is projected to reach USD 6.04 billion by 2033, growing at a CAGR of 4.78% from 2025 to 2033. The demand for these treatments is driven by the increasing prevalence of neglected tropical diseases in low-income regions, as well as advancements in drug development and global health initiatives aimed at eradicating these diseases.

Various global health initiatives, advancements in drug development, and innovative delivery methods greatly influence the neglected tropical disease treatment market. A major factor driving growth in this market is increasing attention from governments and international health organizations. The World Health Organization (WHO) has effectively coordinated mass drug administration (MDA) programs for diseases like lymphatic filariasis, trachoma, and soil-transmitted helminths. According to the World Health Organization (WHO), in April 2025, the United States withdrew funding from NTD programs, impacting 47 campaigns over 19 years. This withdrawal affected 143 million people and disrupted mass treatment efforts. The funding reductions also impeded research, threatening progress toward eliminating diseases such as lymphatic filariasis, onchocerciasis, and schistosomiasis. These efforts, along with commitments from organizations like the Global Fund to Fight AIDS, Tuberculosis, and Malaria, are essential in reducing the disease burden in resource-limited settings, especially in sub-Saharan Africa and Southeast Asia.

Another significant driver of the NTD treatment market is the focus on advancing drug formulations to address the unique challenges posed by neglected diseases. New treatments are being developed to improve efficacy, reduce treatment duration, and enhance patient compliance. According to Reuters, in May 2025, Novartis committed to continuing the production of malaria and leprosy medicines despite potential funding cuts. The company produces 28 million malaria treatment courses annually, mostly sold at not-for-profit prices. Despite challenges from reduced international aid, Novartis remains dedicated to supplying essential medicines, investing nearly USD 490 million in research for malaria and neglected tropical diseases. Despite potential challenges in global health funding, such as cuts in official development assistance, these companies continue to play a vital role in ensuring that treatments remain available to those who need them the most.

In terms of technological advancements, the integration of novel drug delivery systems and digital health innovations is improving both the effectiveness and accessibility of treatments. Nanotechnology, for example, is being explored as a way to enhance the bioavailability of drugs, allowing for more effective treatments even in resource-constrained environments. In July 2025, Swiss medical authorities approved Coartem Baby (also known as Riamet Baby), the first malaria treatment specifically designed for newborns and infants weighing under 11 pounds. Developed by Medicines for Malaria Venture in collaboration with Novartis, the drug addresses a critical treatment gap. It is expected to be rolled out in several African nations, where malaria remains a leading cause of death among children under five. These innovations are not only improving therapeutic outcomes but also making treatments more accessible to populations that previously lacked reliable healthcare options. Additionally, mobile health technologies are helping to bridge the gap in healthcare access, enabling better disease monitoring and management in remote areas, further enhancing the market's potential.

These developments reflect a growing momentum in the NTD treatment space, driven by collaborative efforts between governments, pharmaceutical companies, and global health organizations. With new drug formulations, the commitment of major pharmaceutical players, and technological innovations, the market is poised to continue evolving in its mission to control and ultimately eradicate neglected tropical diseases.

Global Neglected Tropical Disease Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global neglected tropical disease treatment market report based on disease, product, and region:

• Disease Outlook (Revenue, USD Million, 2021 - 2033)
• Dengue
• Rabies
• Trachoma
• Buruli Ulcer
• Yaws
• Leprosy
• Chagas Disease
• Human African Trypanosomiasis (Sleeping Sickness)
• Leishmaniases
• Soil-transmitted Helminthiases
• Others
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Drugs
  • Anti-Parasite
  • Antifungal
  • Antibiotics
  • Others
• Vaccines
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Disease
  • 1.2.2. Product
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Neglected Tropical Disease Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Neglected Tropical Disease Treatment Market: Disease Business Analysis

• 4.1. Disease Market Share, 2024 & 2033
• 4.2. Disease Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Disease, 2021 to 2033 (USD Million)
• 4.4. Dengue
  • 4.4.1. Dengue Market, 2021 - 2033 (USD Million)
• 4.5. Rabies
  • 4.5.1. Rabies Market, 2021 - 2033 (USD Million)
• 4.6. Trachoma
  • 4.6.1. Trachoma Market, 2021 - 2033 (USD Million)
• 4.7. Buruli Ulcer
  • 4.7.1. Buruli Ulcer Market, 2021 - 2033 (USD Million)
• 4.8. Yaws
  • 4.8.1. Yaws Market, 2021 - 2033 (USD Million)
• 4.9. Leprosy
  • 4.9.1. Leprosy Market, 2021 - 2033 (USD Million)
• 4.10. Chagas Disease
  • 4.10.1. Chagas Disease Market, 2021 - 2033 (USD Million)
• 4.11. Human African Trypanosomiasis (Sleeping Sickness)
  • 4.11.1. Human African Trypanosomiasis (Sleeping Sickness) Market, 2021 - 2033 (USD Million)
• 4.12. Leishmaniases
  • 4.12.1. Leishmaniases Market, 2021 - 2033 (USD Million)
• 4.13. Soil-transmitted Helminthiases
  • 4.13.1. Soil-transmitted Helminthiases Market, 2021 - 2033 (USD Million)
• 4.14. Others
  • 4.14.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Neglected Tropical Disease Treatment Market: Product Business Analysis

• 5.1. Product Market Share, 2024 & 2033
• 5.2. Product Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 5.4. Drugs
  • 5.4.1. Drugs Market, 2021 - 2033 (USD Million)
  • 5.4.2. Anti-Parasite
    • 5.4.2.1. Anti-Parasite Market, 2021 - 2033 (USD Million)
  • 5.4.3. Antifungal
    • 5.4.3.1. Antifungal Market, 2021 - 2033 (USD Million)
  • 5.4.4. Antibiotics
    • 5.4.4.1. Antibiotics Market, 2021 - 2033 (USD Million)
  • 5.4.5. Others
    • 5.4.5.1. Others Market, 2021 - 2033 (USD Million)
• 5.5. Vaccines
  • 5.5.1. Vaccines Market, 2021 - 2033 (USD Million)

Chapter 6. Neglected Tropical Disease Treatment Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2033
• 6.2. Regional Market Dashboard
• 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 6.4. North America
  • 6.4.1. North America Neglected Tropical Disease Treatment Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Target Disease Prevalence
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. Reimbursement Framework
    • 6.4.2.5. U.S. Neglected Tropical Disease Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Target Disease Prevalence
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. Reimbursement Framework
    • 6.4.3.5. U.S. Neglected Tropical Disease Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Target Disease Prevalence
    • 6.4.4.3. Regulatory Framework
    • 6.4.4.4. Reimbursement Framework
    • 6.4.4.5. Mexico Neglected Tropical Disease Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Neglected Tropical Disease Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Target Disease Prevalence
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Reimbursement Framework
    • 6.5.2.5. Uk Neglected Tropical Disease Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Target Disease Prevalence
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Reimbursement Framework
    • 6.5.3.5. Germany Neglected Tropical Disease Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Target Disease Prevalence
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. Reimbursement Framework
    • 6.5.4.5. France Neglected Tropical Disease Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Target Disease Prevalence
    • 6.5.5.3. Regulatory Framework
    • 6.5.5.4. Reimbursement Framework
    • 6.5.5.5. Italy Neglected Tropical Disease Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Target Disease Prevalence
    • 6.5.6.3. Regulatory Framework
    • 6.5.6.4. Reimbursement Framework
    • 6.5.6.5. Spain Neglected Tropical Disease Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.7. Denmark
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Target Disease Prevalence
    • 6.5.7.3. Regulatory Framework
    • 6.5.7.4. Reimbursement Framework
    • 6.5.7.5. Denmark Neglected Tropical Disease Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.8. Sweden
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Target Disease Prevalence
    • 6.5.8.3. Regulatory Framework
    • 6.5.8.4. Reimbursement Framework
    • 6.5.8.5. Sweden Neglected Tropical Disease Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.9. Norway
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Target Disease Prevalence
    • 6.5.9.3. Regulatory Framework
    • 6.5.9.4. Reimbursement Framework
    • 6.5.9.5. Norway Neglected Tropical Disease Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Neglected Tropical Disease Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Target Disease Prevalence
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Reimbursement Framework
    • 6.6.2.5. Japan Neglected Tropical Disease Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Target Disease Prevalence
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Reimbursement Framework
    • 6.6.3.5. China Neglected Tropical Disease Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Target Disease Prevalence
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Reimbursement Framework
    • 6.6.4.5. India Neglected Tropical Disease Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.5. Australia
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Target Disease Prevalence
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Reimbursement Framework
    • 6.6.5.5. Australia Neglected Tropical Disease Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.6. South Korea
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Target Disease Prevalence
    • 6.6.6.3. Regulatory Framework
    • 6.6.6.4. Reimbursement Framework
    • 6.6.6.5. South Korea Neglected Tropical Disease Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Target Disease Prevalence
    • 6.6.7.3. Regulatory Framework
    • 6.6.7.4. Reimbursement Framework
    • 6.6.7.5. Thailand Neglected Tropical Disease Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Neglected Tropical Disease Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Target Disease Prevalence
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. Reimbursement Framework
    • 6.7.2.5. Japan Neglected Tropical Disease Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Target Disease Prevalence
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Reimbursement Framework
    • 6.7.3.5. China Neglected Tropical Disease Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Middle East and Africa
  • 6.8.1. Middle East and Africa Neglected Tropical Disease Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Target Disease Prevalence
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. Reimbursement Framework
    • 6.8.2.5. South Africa Neglected Tropical Disease Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Target Disease Prevalence
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. Reimbursement Framework
    • 6.8.3.5. Saudi Arabia Neglected Tropical Disease Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Target Disease Prevalence
    • 6.8.4.3. Regulatory Framework
    • 6.8.4.4. Reimbursement Framework
    • 6.8.4.5. UAE Neglected Tropical Disease Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Target Disease Prevalence
    • 6.8.5.3. Regulatory Framework
    • 6.8.5.4. Reimbursement Framework
    • 6.8.5.5. Kuwait Neglected Tropical Disease Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. F. Hoffmann-La Roche Ltd
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Disease Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Bayer AG
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Disease Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. GlaxoSmithKline plc
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Disease Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Novartis AG
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Disease Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Pfizer, Inc.
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Disease Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Eisai Co. Ltd.
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Disease Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Sanofi
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Disease Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Astellas Pharma
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Disease Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Takeda Pharmaceutical Company Limited
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Disease Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. Gilead Sciences.
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Disease Benchmarking
    • 7.5.10.4. Strategic Initiatives